Radioimmunoassay Market Size, Share & Trends Analysis Report By Product (Analyzers, Reagents & Kits), By Application (Research, Clinical Diagnostics), By End Use (Hospitals, Laboratory), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED: April 17, 2025

PAGES: 320 Pages

DELIVERY TIME: 2-10 business days

SELECT AN OPTION

The global radioimmunoassay market size is expected to reach USD 1.79 billion by 2030, registering a CAGR of 2.93% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by its critical role in highly sensitive and specific diagnostic applications. RIA remains a major solution for the detection of minute concentrations of hormones, drugs, tumor markers, and infectious agents despite the rise of newer immunoassay techniques. A key market driver is the rising prevalence of chronic and infectious diseases worldwide. According to UNAIDS, nearly 39.9 million people globally were living with HIV in 2023, with 1.3 million new infections, reflecting the ongoing need for accurate and reliable testing methodologies such as RIA. In addition, the increasing incidence of thyroid disorders and certain cancers has amplified the demand for precise endocrine and oncology diagnostics.

Recent advancements in RIA technologies and reagents have also contributed to market growth. Companies such as Medipan GmbH have enhanced the shelf life of RIA kits for TSH, Tg, and Calcitonin, improving laboratory efficiency. Additionally, their streamlined SELco TRAb 1-step assay, launched in 2022, has improved turnaround time and workflow simplicity in detecting thyroid antibodies. Strategic collaborations and acquisitions further highlight market consolidation and innovation. For instance, DiaSorin's acquisition of Luminex Corporation has expanded its multiplex testing capabilities, reinforcing its position in specialty diagnostics, including RIA. Moreover, DIAsource's milestone agreement with Svar Life Science (formerly Euro Diagnostica) supports the development of advanced immunoassay solutions, further boosting RIA technology dissemination.

The radioimmunoassay market is also shaped by its relevance in both clinical diagnostics and research. Clinical settings, especially hospitals and diagnostic laboratories, account for a substantial market share due to the routine use of RIA in hormonal assays and allergy testing. Meanwhile, research laboratories drive the fastest growth, utilizing RIA's high specificity for biomedical studies. The introduction of advanced analyzers and automated gamma counters, like those from LabLogic Systems, supports the modernization of RIA workflows and widens access to high-throughput applications.

Advancements in lab-on-a-chip (LOC) technology have revolutionized traditional radioimmunoassay (RIA). The development of microfluidic RIA platforms, or μ-RIA, has significantly reduced analysis times to approximately five minutes and minimized reagent consumption. These improvements address previous limitations of RIA, such as lengthy incubation periods and radioactive waste production, thereby enhancing the technique's applicability in clinical diagnostics. These developments underscore a concerted effort to refine radioactive labeling and radioimmunoassay methodologies, aiming for greater precision, efficiency, and safety in diagnostic imaging and targeted. Recently, in March 2025, researchers from the University of Alberta introduced a novel molecular imaging test that combines the monoclonal antibody panitumumab with the radioisotope copper-64. Panitumumab targets the epidermal growth factor receptor (EGFR), commonly overexpressed in non-small-cell lung cancer cells. When labeled with copper-64, this conjugate enables precise PET imaging, facilitating early detection and monitoring of lung cancer. This hybrid approach offers a non-invasive alternative to traditional biopsies, potentially improving patient outcomes through timely intervention.

Radioimmunoassay Market Report Highlights:

The reagent and kits led the product segment in 2024 with a 73.23% revenue share. The increasing demand for reliable diagnostic tools in endocrine, oncology, infectious disease, and autoimmune disorder testing has significantly boosted the consumption of RIA reagents and kits across laboratories and hospitals. These kits typically include radioactively labeled antigens or antibodies (commonly using Iodine-125), buffers, standards, and separation reagents. The high sensitivity and specificity of these kits make them indispensable in clinical laboratories for detecting hormones such as TSH, insulin, cortisol, testosterone, and estradiol. For example, PerkinElmer and DIAsource ImmunoAssays offer a wide range of RIA kits for thyroid function testing (like TSH and Calcitonin), fertility hormones, and tumor markers, supporting routine screening and specialized diagnostics. Whereas analyzers is expected to be the fastest-growing segment during the forecast period.
The clinical diagnostics led the application segment in the radioimmunoassay industry in 2024 with a 76.33% share in terms of revenue, owing to the widespread use of RIA techniques for routine and specialized medical testing. This dominance is primarily attributed to the method's exceptional sensitivity and specificity in detecting minute concentrations of biological markers, making it invaluable for accurate diagnosis, disease monitoring, and therapeutic decision-making. Whereas research is expected to be the fastest-growing segment during the forecast period.
The hospital led the end use segment in the market in 2024 with a 32.54% revenue share, driven by the hospitals' comprehensive diagnostic capabilities and the increasing prevalence of diseases requiring precise biomarker detection. RIA's exceptional sensitivity and specificity make it indispensable in hospital settings for accurately measuring low concentrations of hormones, drugs, and other substances in patient samples. In addition, the adoption of automated and advanced RIA systems in hospitals has streamlined workflows, reduced turnaround times, and improved result accuracy.
North America dominated the global market for radioimmunoassay with a revenue share of 47.43% in 2024. The growth is driven by the presence of advanced healthcare infrastructure, robust research and development (R&D) activities, and a high prevalence of chronic diseases necessitating precise diagnostic tools. Further, supportive policies and reimbursement frameworks enhance the adoption and integration of RIA in clinical diagnostics.

Product Code: GVR-4-68040-554-8

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. End Use
1.3. Regional Scope
1.4. Estimates and Forecast Timeline
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
1.7. Details of primary research
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity flow analysis (Model 1)
  - 1.9.1.1. Approach 1: Commodity flow approach
- 1.9.2. Volume price analysis (Model 2)
  - 1.9.2.1. Approach 2: Volume price analysis
1.10. Research Scope and Assumptions
- 1.10.1. List of Secondary Sources
- 1.10.2. List of Primary Sources
- 1.10.3. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Radioimmunoassay Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
  - 3.2.1.1. Rising Prevalence 0f Chronic and Infectious Diseases
  - 3.2.1.2. High Sensitivity and Specificity of RIA Techniques
  - 3.2.1.3. Advancements in Radiolabeled Reagents and Assay Technologies
  - 3.2.1.4. The Rising Amount of Blood Donations in Blood Banks
- 3.2.2. Market Restraints Analysis
  - 3.2.2.1. Presence of Ambiguous Regulatory Framework
  - 3.2.2.2. High Cost of RIA Equipment
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Supply Chain Analysis
- 3.2.5. Distribution Channel
  - 3.2.5.1. Direct Sales
  - 3.2.5.2. Distributors Network
  - 3.2.5.3. E-commerce and Online Platforms
  - 3.2.5.4. Major Distributors
3.3. Radioimmunoassay Market Analysis Tools
- 3.3.1. Porter's Analysis
  - 3.3.1.1. Bargaining power of the suppliers
  - 3.3.1.2. Bargaining power of the buyers
  - 3.3.1.3. Threats of substitution
  - 3.3.1.4. Threats from new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Economic and Social landscape
  - 3.3.2.3. Technological landscape
  - 3.3.2.4. Legal landscape
3.4. Reimbursement Overview
3.5. Pricing Analysis

Chapter 4. Radioimmunoassay Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Radioimmunoassay Market: Product Movement Analysis, 2024 & 2030 (USD Million)
4.3. Analyzers
- 4.3.1. Analyzers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Reagents and Kits
- 4.4.1. Reagents and Kits Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Radioimmunoassay Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Radioimmunoassay Market: Application Movement Analysis, 2024 & 2030 (USD Million)
5.3. Research
- 5.3.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Clinical Diagnostics
- 5.4.1. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Radioimmunoassay Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Radioimmunoassay Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
6.3. Hospitals
- 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Clinical Diagnostics Laboratories
- 6.4.1. Clinical Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Pharmaceutical Industries
- 6.5.1. Pharmaceutical Industries Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Radioimmunoassay Market: Regional Estimates & Trend Analysis

7.1. Radioimmunoassay Market Share, By Region, 2024 & 2030 (USD Million)
7.2. North America
- 7.2.1. North America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. Key Country Dynamics
  - 7.2.2.2. Regulatory Landscape/Reimbursement Scenario
  - 7.2.2.3. Competitive Insights
  - 7.2.2.4. U.S. Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Key Country Dynamics
  - 7.2.3.2. Regulatory Landscape/Reimbursement Scenario
  - 7.2.3.3. Competitive Insights
  - 7.2.3.4. Canada Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Key Country Dynamics
  - 7.2.4.2. Regulatory Landscape/Reimbursement Scenario
  - 7.2.4.3. Competitive Insights
  - 7.2.4.4. Mexico Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Regulatory Landscape/Reimbursement Scenario
  - 7.3.2.3. Competitive Insights
  - 7.3.2.4. UK Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Regulatory Landscape/Reimbursement Scenario
  - 7.3.3.3. Competitive Insights
  - 7.3.3.4. Germany Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Regulatory Landscape/Reimbursement Scenario
  - 7.3.4.3. Competitive Insights
  - 7.3.4.4. France Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Key Country Dynamics
  - 7.3.5.2. Regulatory Landscape/Reimbursement Scenario
  - 7.3.5.3. Competitive Insights
  - 7.3.5.4. Italy Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Key Country Dynamics
  - 7.3.6.2. Regulatory Landscape/Reimbursement Scenario
  - 7.3.6.3. Competitive Insights
  - 7.3.6.4. Spain Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Sweden
  - 7.3.7.1. Key Country Dynamics
  - 7.3.7.2. Regulatory Landscape/Reimbursement Scenario
  - 7.3.7.3. Competitive Insights
  - 7.3.7.4. Sweden Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Denmark
  - 7.3.8.1. Key Country Dynamics
  - 7.3.8.2. Regulatory Landscape/Reimbursement Scenario
  - 7.3.8.3. Competitive Insights
  - 7.3.8.4. Denmark Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Key Country Dynamics
  - 7.3.9.2. Regulatory Landscape/Reimbursement Scenario
  - 7.3.9.3. Competitive Insights
  - 7.3.9.4. Norway Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Landscape/Reimbursement Scenario
  - 7.4.2.3. Competitive Insights
  - 7.4.2.4. China Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Landscape/Reimbursement Scenario
  - 7.4.3.3. Competitive Insights
  - 7.4.3.4. Japan Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Regulatory Landscape/Reimbursement Scenario
  - 7.4.4.3. Competitive Insights
  - 7.4.4.4. India Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. Key Country Dynamics
  - 7.4.5.2. Regulatory Landscape/Reimbursement Scenario
  - 7.4.5.3. Competitive Insights
  - 7.4.5.4. South Korea Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Key Country Dynamics
  - 7.4.6.2. Regulatory Landscape/Reimbursement Scenario
  - 7.4.6.3. Competitive Insights
  - 7.4.6.4. Australia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Key Country Dynamics
  - 7.4.7.2. Regulatory Landscape/Reimbursement Scenario
  - 7.4.7.3. Competitive Insights
  - 7.4.7.4. Thailand Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Landscape/Reimbursement Scenario
  - 7.5.2.3. Competitive Insights
  - 7.5.2.4. Brazil Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Landscape/Reimbursement Scenario
  - 7.5.3.3. Competitive Insights
  - 7.5.3.4. Argentina Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Landscape/Reimbursement Scenario
  - 7.6.2.3. Competitive Insights
  - 7.6.2.4. Saudi Arabia Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Landscape/Reimbursement Scenario
  - 7.6.3.3. Competitive Insights
  - 7.6.3.4. UAE Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Landscape/Reimbursement Scenario
  - 7.6.4.3. Competitive Insights
  - 7.6.4.4. South Africa Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Landscape/Reimbursement Scenario
  - 7.6.5.3. Competitive Insights
  - 7.6.5.4. Kuwait Radioimmunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Global Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Strategy Mapping
- 8.5.1. Expansion
- 8.5.2. Mergers & Acquisition
- 8.5.3. Partnerships & Collaborations
- 8.5.4. New Product Launches
- 8.5.5. Research And Development
8.6. Company Profiles
- 8.6.1. DIAsource
  - 8.6.1.1. Participant's Overview
  - 8.6.1.2. Financial Performance
  - 8.6.1.3. Product Benchmarking
  - 8.6.1.4. Recent Developments
- 8.6.2. Tecan Trading AG
  - 8.6.2.1. Participant's Overview
  - 8.6.2.2. Financial Performance
  - 8.6.2.3. Product Benchmarking
  - 8.6.2.4. Recent Developments
- 8.6.3. PerkinElmer
  - 8.6.3.1. Participant's Overview
  - 8.6.3.2. Financial Performance
  - 8.6.3.3. Product Benchmarking
  - 8.6.3.4. Recent Developments
- 8.6.4. DRG International Inc.
  - 8.6.4.1. Participant's Overview
  - 8.6.4.2. Financial Performance
  - 8.6.4.3. Product Benchmarking
  - 8.6.4.4. Recent Developments
- 8.6.5. Oxford BioSystems
  - 8.6.5.1. Participant's Overview
  - 8.6.5.2. Financial Performance
  - 8.6.5.3. Product Benchmarking
  - 8.6.5.4. Recent Developments
- 8.6.6. DiaSorin S.p.A.
  - 8.6.6.1. Participant's Overview
  - 8.6.6.2. Financial Performance
  - 8.6.6.3. Product Benchmarking
  - 8.6.6.4. Recent Developments
- 8.6.7. Eurodiagnostico, S.L.
  - 8.6.7.1. Participant's Overview
  - 8.6.7.2. Financial Performance
  - 8.6.7.3. Product Benchmarking
  - 8.6.7.4. Recent Developments
- 8.6.8. MP Biomedicals
  - 8.6.8.1. Participant's Overview
  - 8.6.8.2. Financial Performance
  - 8.6.8.3. Product Benchmarking
  - 8.6.8.4. Recent Developments
- 8.6.9. Merck KGaA
  - 8.6.9.1. Participant's Overview
  - 8.6.9.2. Financial Performance
  - 8.6.9.3. Product Benchmarking
  - 8.6.9.4. Recent Developments

Product Code: GVR-4-68040-554-8

List of Tables

Table 1 List of abbreviation
Table 2 North America radioimmunoassay market, by region, 2018 - 2030 (USD Million)
Table 3 North America radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 4 North America radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 5 North America radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 6 U.S. radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 7 U.S. radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 8 U.S. radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 9 Canada radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 10 Canada radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 11 Canada radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 12 Mexico radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 13 Mexico radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 14 Mexico radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 15 Europe radioimmunoassay market, by region, 2018 - 2030 (USD Million)
Table 16 Europe radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 17 Europe radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 18 Europe radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 19 Germany radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 20 Germany radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 21 Germany radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 22 UK radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 23 UK radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 24 UK radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 25 France radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 26 France radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 27 France radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 28 Italy radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 29 Italy radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 30 Italy radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 31 Spain radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 32 Spain radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 33 Spain radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 34 Denmark radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 35 Denmark radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 36 Denmark radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 37 Sweden radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 38 Sweden radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 39 Sweden radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 40 Norway radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 41 Norway radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 42 Norway radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 43 Asia Pacific radioimmunoassay market, by region, 2018 - 2030 (USD Million)
Table 44 Asia Pacific radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 45 Asia Pacific radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 46 Asia Pacific radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 47 China radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 48 China radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 49 China radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 50 Japan radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 51 Japan radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 52 Japan radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 53 India radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 54 India radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 55 India radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 56 South Korea radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 57 South Korea radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 58 South Korea radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 59 Australia radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 60 Australia radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 61 Australia radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 62 Thailand radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 63 Thailand radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 64 Thailand radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 65 Latin America radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 66 Latin America radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 67 Latin America radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 68 Brazil radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 69 Brazil radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 70 Brazil radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 71 Argentina radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 72 Argentina radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 73 Argentina radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 74 MEA radioimmunoassay market, by region, 2018 - 2030 (USD Million)
Table 75 MEA radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 76 MEA radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 77 MEA radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 78 South Africa radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 79 South Africa radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 80 South Africa radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 81 Saudi Arabia radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 84 UAE radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 85 UAE radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 86 UAE radioimmunoassay market, by end use, 2018 - 2030 (USD Million)
Table 87 Kuwait radioimmunoassay market, by product, 2018 - 2030 (USD Million)
Table 88 Kuwait radioimmunoassay market, by application, 2018 - 2030 (USD Million)
Table 89 Kuwait radioimmunoassay market, by end use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Radioimmunoassay market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Parent market outlook, 2024
Fig. 10 Radioimmunoassay market driver impact
Fig. 11 Radioimmunoassay market restraint impact
Fig. 12 Market entry strategy
Fig. 13 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 14 Porter's five forces analysis
Fig. 15 Radioimmunoassay market: Product outlook and key takeaways
Fig. 16 Radioimmunoassay market: Products movement analysis
Fig. 17 Analyzers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Reagents and kits market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Radioimmunoassay market: Application outlook and key takeaways
Fig. 20 Radioimmunoassay market: Application movement analysis
Fig. 21 Research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Clinical Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Radioimmunoassay market: End use outlook and key takeaways
Fig. 24 Radioimmunoassay market: End use movement analysis
Fig. 25 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Clinical diagnostics laboratories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Pharmaceutical industries market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Radioimmunoassay Market: Regional outlook and key takeaways
Fig. 30 Radioimmunoassay market: Regional movement analysis
Fig. 31 North America
Fig. 32 North America. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 U.S. key country dynamics
Fig. 34 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Canada key country dynamics
Fig. 36 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Mexico key country dynamics
Fig. 38 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Europe
Fig. 40 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 UK key country dynamics
Fig. 42 UK market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Germany key country dynamics
Fig. 44 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Spain key country dynamics
Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 France key country dynamics
Fig. 48 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Italy key country dynamics
Fig. 50 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Denmark key country dynamics
Fig. 52 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Sweden key country dynamics
Fig. 54 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Norway key country dynamics
Fig. 56 Norway market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Asia Pacific
Fig. 58 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Japan key country dynamics
Fig. 60 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 China key country dynamics
Fig. 62 China. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 India key country dynamics
Fig. 64 India. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 South Korea key country dynamics
Fig. 66 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Thailand key country dynamics
Fig. 68 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Australia key country dynamics
Fig. 70 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Latin America
Fig. 72 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Brazil key country dynamics
Fig. 74 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Argentina key country dynamics
Fig. 76 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 MEA
Fig. 78 MEA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 South Africa key country dynamics
Fig. 80 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 UAE key country dynamics
Fig. 82 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Saudi Arabia key country dynamics
Fig. 84 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Kuwait key country dynamics
Fig. 86 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)